Skip to content
Menu

HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsDowngradesPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.

HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.

Read at benzinga.com

← All stock news